Where does Blackthorn Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Blackthorn Therapeutics, Inc. ranks #25,893 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Blackthorn Therapeutics, Inc. hold?

Blackthorn Therapeutics, Inc. holds 10 US utility patents granted between 2020 and 2024, spanning 10 technology areas.

What is Blackthorn Therapeutics, Inc.'s Innovation Score?

Blackthorn Therapeutics, Inc. has an Innovation Score of 37.3 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Blackthorn Therapeutics, Inc. focus on?

Blackthorn Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents, ranking #3,434 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Blackthorn Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Blackthorn Therapeutics, Inc..

What does claim depth mean for Blackthorn Therapeutics, Inc.'s patents?

Blackthorn Therapeutics, Inc.'s patents average 31.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Blackthorn Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Blackthorn Therapeutics, Inc.

USPTO PatentsView assignee record - 10 granted patents across 10 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Blackthorn ranks #25,893 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 10 technology areas.

#25,893
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.3/100): 31.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25893 · US Corporation #25,893 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 10 grants
MID-PACK #25,893/49,997
PHOTO-FINISH Biosearch
CPC-FOCUS A61P · 10 areas
INNOV-THIN 37.3/100
CLAIMS-DENSE 31.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2024 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Biosearch Technologies, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Blackthorn’s 37.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (22%) Velocity 2.9 pts (8%) Breadth 11.2 pts (30%) Claim depth 15.0 pts (40%)

Qualcomm Incorporated · highest

85
Blackthorn Therapeut… · this assignee

37
3D Lighting… · lowest

7

What this shows Blackthorn's Innovation Score is 37.3/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Blackthorn?

Each dot is one of Blackthorn’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Blackthorn’s own 31.8 claims/patent is ABOVE the 14.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Blackthorn vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Blackthorn's grants concentrate

Blackthorn Therapeutics, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 50% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (5 grants) versus a trough of 1 in 2024. By volume, Blackthorn sits between Biosearch Technologies, Inc. and Bobst Grenchen AG.

Blackthorn's three-year grant acceleration

Blackthorn Therapeutics, Inc. shows 3 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Biosearch

10
Biovest Internati…

10
Birko

10
Bizerba & KG

10
Blox

10
Blueplanet

10
BMC

10
Bobst Grenchen

10
Blackthorn Therap… ◀

10

What this shows Blackthorn holds 10 patents at rank #25,863, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Blackthorn

By rank, the assignees closest to #25,863 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Blackthorn's primary technology class.

Blackthorn's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Blackthorn Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	20.0%
2021	5	50.0%
2022	2	20.0%
2024	1	10.0%

Which technologies does Blackthorn Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

C07D - Heterocyclic Compounds 5

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 5

A61B - DIAGNOSIS; SURGERY; Identification 3

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

G06V - Image OR Video Recognition OR Understanding 1

G06F - Electric Digital Data Processing 1

G06N - Computing Arrangements Based ON Specific Computational Models 1

G06T - Image Data Processing OR Generation, IN General 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Blackthorn Therapeutics, Inc.'s patent record in context - here's where to go next.

Blackthorn Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 50% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #25,893 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Blackthorn Therapeutics, Inc. against Biosearch Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.